The global Alzheimer's disease diagnostics market is expanding rapidly due to advances in early detection methods and growing clinical demand for brain imaging. Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) is positioning itself within this sector by preparing to open specialized neuroimaging clinics in the United States.
Market Opportunity in Alzheimer's Diagnostics
According to a May 2026 report from Precedence Research, the global Alzheimer's disease diagnostics market was valued at US$9.94 billion in 2025 and is projected to reach US$27.90 billion by 2035.
Brain imaging accounted for 38% of that market in 2025, driven by the need to identify early structural and amyloid markers. The U.S. Food and Drug Administration recently cleared the first blood test to help detect Alzheimer's disease, offering a less invasive screening option that may still require confirmatory imaging.
Why Grey Matters Health Inc. Stands Out
Grey Matters Health Inc. plans to establish a network of private U.S. neuroimaging clinics using FDA-cleared, brain-specific PET scanning technology. The company intends to focus initially on Alzheimer's disease detection while exploring additional applications such as epilepsy, Parkinson's disease, multiple sclerosis, and brain cancers.
This targeted approach differentiates it from broader diagnostic providers by emphasizing dedicated brain-optimized equipment and Medicare, Medicaid, and private insurance reimbursement of at least CA$4,500 per scan.
Recent Financing Supports Clinic Launch
Grey Matters Health Inc. announced an increase to its non-brokered private placement financing to CA$1.25 million and the closing of the second and final tranche of the offering. The second tranche generated gross proceeds of CA$750,000 through the sale of 1,875,000 units at CA$0.40 per unit. Combined with the first tranche, which closed on June 5, 2026, the total financing reached CA$1.25 million from 3,125,000 units.
Certain insiders participated for CA$449,000 under exemptions from valuation and minority approval requirements. The company paid cash finder's fees of CA$28,000 and issued 70,000 finder's warrants for the second tranche. Grey Matters said proceeds will advance its Alzheimer's Disease program toward the first U.S. clinic, along with general and administrative expenses and working capital. All securities are subject to a four-month-plus-one-day hold period.
Key Investor Takeaways
- Grey Matters Health Inc. is preparing dedicated brain PET clinics using the CareMiBrain system, the first such units planned for U.S. operation.
- The company closed a CA$1.25 million financing that provides capital to open its initial clinic and cover operating needs.
- Reimbursement rates of at least CA$4,500 per scan from Medicare, Medicaid, and private payers support the business model.
- The Alzheimer's diagnostics market is projected to grow from US$9.94 billion in 2025 to US$27.90 billion by 2035, with brain imaging holding a significant share.
- Analyst Stewart Thomson previously set price targets of CA$0.08, CA$0.17, and CA$0.40 that have all been achieved.
- Management and insiders hold approximately 11% of shares, while institutions own about 21%.
Alzheimer's Program and Planned Clinic Network
The company has outlined plans for up to 200 neuroimaging clinic locations across the United States. According to the investor presentation, the CareMiBrain PET Brain Scanning System received FDA clearance in 2024 and carries a CE Mark.
The compact system performs brain-specific PET scans without a CT component. Confirmatory beta-amyloid PET scans are required before patients receive newly approved antibody therapies, and follow-up scans may monitor treatment response. The Alzheimer's Association has noted that blood-based biomarker tests meeting performance thresholds can serve as a triage tool before PET imaging or, in some cases, as a substitute.
Industry Trends Supporting Neuroimaging
As reported by Reuters on May 16, the FDA clearance of Fujirebio Diagnostics' Lumipulse test marks the first approved blood test for Alzheimer's detection. The test measures amyloid-related biomarkers, and positive results would still require advanced evaluation.
Streetwise Ownership Overview*
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB)
| Strike Price | Number | Expiry Date |
|---|---|---|
| $2.4 | 340,000 | 08/01/26 |
| $2.4 | 4,480 | 08/01/26 |
| $2.4 | 196,000 | 08/19/26 |
| $2.4 | 4,000 | 08/19/26 |
| $9.38 | 114,887 | 07/04/27 |
| $10.31 | 4,338 | 07/04/27 |
| $10.31 | 8,192 | 08/22/27 |
| $10.63 | 149,560 | 08/22/27 |
| $25 | 450,000 | 05/22/30 |
| $2.5 | 550,000 | 05/22/30 |
| $15 | 517,500 | 06/30/30 |
| $15 | 116,667 | 07/24/30 |
| $1.5 | 126,429 | 11/14/30 |
| $1.5 | 150,000 | 11/28/30 |
| $1.5 | 251,786 | 12/23/30 |
| $1.5 | 83,929 | 12/31/30 |
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 04/21/26 | AGN | 10 | GREY | 1 |
| 03/03/23 | AGN | 1 | AGN | 4 |
| 11/24/21 | AGN | 100 | AGN | 1 |
| 02/19/19 | BTH | 1 | AGN | 1 |
| 10/17/18 | BTH | 2 | BTH | 1 |
Research published in JAMA Network Open found that approximately 76% of FDA-authorized AI-enabled medical devices are tied to radiology, underscoring imaging as the leading area for AI adoption in healthcare. The Alzheimer's Association reported that blood-based biomarker tests meeting specific performance thresholds may serve either as a triage tool before PET imaging.
Analyst Views and Valuation Context
1In a March 26 report, analyst Stewart Thomson discussed Grey Matters Health Inc.'s plans to enter the Alzheimer's disease diagnostics market through a network of specialized neuroimaging clinics in the United States. Thomson wrote that the strategy centers on brain-optimized PET imaging and referenced the company's target of a CA$6.9 billion emerging market.
He assigned a Technical Rating of Strong Speculative Buy with short-, medium-, and long-term price targets of CA$0.08, CA$0.17, and CA$0.40 that have since been achieved.
Share Structure and Ownership
2Management and insiders own about 11% of the company, and about 21% is owned by institutions. The rest is with retail. Top shareholders include Alpha North Asset Management with 20.52%, Chief Executive Officer Christopher Moreau with 5.05%, Chairman of the Board Harry Bloomfield with 1.97%, Chief Financial Officer James Kinley with 1.4%, and Director Rajpaul Attariwala with 1.2%. Grey Matters has 54.1 million outstanding shares and a market cap of CA$1.37 million, with a 52-week range of CA$0.035 - CA$0.10.
Common Questions from Investors
What will the recent financing be used for? Proceeds will advance the Alzheimer's program toward the first U.S. brain-specific neuroimaging clinic and support general and administrative expenses and working capital.
Are the planned scans covered by insurance? Grey Matters states that scans using the CareMiBrain system are covered by Medicare, Medicaid, and private insurance, with reimbursement of at least CA$4,500 per scan.
How many clinics does the company plan to open? The investor presentation outlines a target network of 200 neuroimaging clinic locations across the United States.
What technology will the clinics use? The clinics are expected to utilize the CareMiBrain PET Brain Scanning System, an FDA-cleared, compact brain-specific system that received clearance in 2024.
Is insider participation in the financing disclosed? Yes, insiders participated for CA$449,000, and the company relied on exemptions under Multilateral Instrument 61-101 because the amounts did not exceed 25% of market capitalization.
Retail investors evaluating Grey Matters Health Inc. should consider both the growth potential of the Alzheimer's diagnostics sector and the execution risks associated with opening new specialized clinics. The recent financing provides near-term capital, yet successful clinic rollout and patient volume will ultimately determine long-term outcomes.
| Want to be the first to know about interesting Healthcare Services and Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Grey Matters Health has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026
- For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
- Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
2. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
